ArticleAsiaIntervention2025
Assessing mortality rates and predictors of cardiac death in diabetic and non-diabetic patients after left main percutaneous coronary intervention with the Resolute zotarolimus-eluting stent in Bangladesh: a comprehensive analysis.
Article in AsiaIntervention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Managing coronary artery disease in diabetic patients, especially left main coronary artery (LMCA) disease, requires complex decision-making. Drug-eluting stents, such as the Resolute zotarolimus-eluting stent (ZES), provide a less invasive alternative to coronary artery bypass grafting for revascularisation. Aims: We aimed to compare the mortality rates between patients with or without diabetes following left main percutaneous coronary intervention (PCI) using the Resolute ZES and to assess the major predictors of cardiac death based on baseline characteristics, lesion features, and procedural details. Methods: This retrospective cohort study conducted between 2010 and 2019 at a tertiary care cardiac hospital in Bangladesh involved 884 patients undergoing left main PCI with the Resolute ZES. The primary endpoint of this study was the difference in mortality between the two groups (diabetes vs non-diabetes). Descriptive and inferential statistics were used to analyse patient demographics, clinical characteristics, and outcomes. Survival analyses utilised Kaplan-Meier curves and Cox proportional hazards models for both univariate and multivariate analyses. Results: All-cause mortality (hazard ratio [HR] 0.87, 95% confidence interval [CI]: 0.47-1.61; p=0.67) and cardiac death rates (HR 0.84, 95% CI: 0.43-1.65; p=0.61) were similar for the diabetes and non-diabetes groups, and the predictors of cardiac death in the multivariate analysis included age (HR 1.09, 95% CI: 1.06-1.13; p<0.001), elevated creatinine levels (HR 4.45, 95% CI: 1.80-11.02; p<0.001), and post-dilatation (HR 0.10, 95% CI: 0.03-0.39; p<0.001); the Medina classification also showed a significant association with cardiac death. Conclusions: The use of the Resolute ZES was associated with comparable outcomes in diabetic and non-diabetic patients undergoing left main PCI. Age, renal function, and certain procedural techniques are key predictors of cardiac death, emphasising the need for individualised patient assessment in LMCA disease management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.